it's interesting one person sees bio being not good because...

it's interesting one person sees bio being not good because of cash runway and a long ROI (why are you on a early bio page then not sure)

while another person acknowledge that's the investment we are in and it's like saying bio will be bio.

given we ARE BIO and we already accepted this fact one should focus on how little (bio here remember don't forget) our burn rate actually is. how great the clinical arm is for a revenue stream (a bio with revenue!!!!) how the RWD/ clinics have on ramped and reduced trial cost and recruitment of participants cost.

like all large projects funding is for specific goals and stages. if someone wants to give a big cash injection you usually can give them a bit of a discount (like we all expect even when buying apples in bulk).

CR before results to see who wants to place their bets. CR after results (all going well)

the MDMA on ramp won't be fast it will start with #1 patient BUT first country in the world and we are BIO not having to do a big trial (10) to get your first feedback loop we can do 1+1+1 tweak as go via the clinic and the. turn into a detailed trial.

so yes we are bio, and there is a long lead time to ROI but this bio has one of the fastest paths via RWD has
de-risked via clinics and RWD, has a revenue steam (unheard of for an early bio), a fast enrolment path via the clinics.

don't forget emds work with the govt and the only tga registered device can't remember openly I think it was called.